Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
- CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options
- Prior studies demonstrated IV glibenclamide may potentially improve functional outcomes and reduce mortality, supported by imaging measures of brain swelling and biomarkers
- Study initiation advances Biogen’s position in its emerging growth area of acute neurology
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) announced today the enrollment of the first patient in the global Phase 3 clinical study CHARM, designed to evaluate BIIB093 (intravenous (IV) glibenclamide) for the prevention and treatment of severe cerebral edema in large hemispheric infarction (LHI), one of the most severe types of ischemic stroke where brain swelling (cerebral edema) often leads to high morbidity and mortality.
“As pioneers in neuroscience, Biogen is dedicated to advancing innovative approaches for investigational drugs in acute neurological conditions with limited or no treatments by leveraging our core expertise,” said Michael Ehlers, M.D., Ph.D., executive vice president, research and development at Biogen. “We believe IV glibenclamide could represent a first-in-class therapy with the aim of giving physicians an effective option to improve patient outcomes and reduce mortality risk. LHI is a severe type of ischemic stroke with high mortality (40 percent to 80 percent) and no currently available therapy. BIIB093 has the potential to be the first major innovation in stroke in over 20 years, and we believe the advancement to Phase 3 represents a significant milestone in our stroke clinical program.”
The CHARM study is an international, multicenter, randomized, double-blind, placebo-controlled, Phase 3 study that aims to enroll 680 patients with LHI in approximately 20 countries. It will evaluate the efficacy and safety of IV glibenclamide treatment within 10 hours following stroke onset. The primary endpoint is the modified Rankin Scale (mRS), a functional outcome, assessed at 90 days.
Each year approximately 1.7 million ischemic strokes occur in the U.S., Europe and Japan, and approximately 15 percent of these are classified as LHI. In preclinical studies, IV glibenclamide has been shown to inhibit SUR1-TRPM4 channels that mediate stroke-related brain swelling. Phase 2 proof-of-concept studies have demonstrated the potential of IV glibenclamide to reduce brain swelling associated with disability and mortality in individuals with LHI. IV glibenclamide was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted the CHARM study Special Protocol Assessment and IV glibenclamide Fast Track Designation.
For more information about the Phase 3 study, visit www.clinicaltrials.gov (NCT02864953).
About BIIB093 (IV Glibenclamide)
IV glibenclamide is an investigational compound in development for the prevention and treatment of severe cerebral edema due to large hemispheric infarctions (LHI). IV glibenclamide is a high affinity inhibitor of SUR1-TRPM4 channels, which are upregulated following ischemia and trauma. Opening of these channels can lead to cerebral edema, midline shift, increased intracranial pressure and brain herniation, resulting in permanent disability or death. Biogen acquired the IV glibenclamide asset from Remedy Pharmaceuticals following completion of the Phase 2 GAMES-RP study.
IV glibenclamide was previously evaluated in the Phase 2 GAMES-RP study with a primary endpoint measuring the proportion of patients who achieved an mRS score of 0–4 at 90 days without undergoing decompressive craniectomy. Although this study did not meet the primary endpoint, IV glibenclamide demonstrated potential positive effects on functional outcomes and mortality, supported by biomarkers and imaging measures of brain swelling. Mortality at 30 days was reduced from 36 percent in the placebo group to 15 percent in IV glibenclamide-treated patients (p=0.03). In addition, in patients 70 years of age and younger, 90-day functional outcomes were statistically significantly improved (p=0.048) in the IV glibenclamide group versus placebo. These clinical effects correlated with a significant decrease in the concentration of metalloproteinase-9 (MMP-9), a biomarker associated with extracellular matrix breakdown following stroke, in the IV glibenclamide-treated group. The IV glibenclamide-treated group at approximately 72 hours showed a significant reduction in midline shift (p=0.0006), an imaging marker of neurological deterioration and poor outcomes including death.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor Statement
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential clinical effects of IV glibenclamide, the potential of Biogen’s commercial business and pipeline programs, including IV glibenclamide and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by words such as “aim,” “anticipate, “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation, uncertainty of success in the development and potential commercialization of IV glibenclamide; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including IV glibenclamide; the occurrence of adverse safety events; unexpected costs or delays; failure to protect and enforce Biogen’s data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; or we may encounter other unexpected hurdles. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
+1 617 679 4945
+1 781 464 4471
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
CTG Promotes Three Long-time Business Leaders in Europe15.2.2019 15:00:00 | Pressemelding
Bob Daelman, Guido Helsloot and Rénald Wauthier named Vice Presidents BUFFALO, N.Y., Feb. 15, 2019 (GLOBE NEWSWIRE) -- CTG (NASDAQ: CTG), a leading provider of information technology (IT) solutions and services in North America and Western Europe, announced today that three of the Company’s high-performing managers in its European business, Bob Daelman, Guido Helsloot and Rénald Wauthier, have each been named vice president. “Bob Daelman and Rénald Wauthier have proven track records of significantly expanding their respective businesses in Europe. Guido Helsloot has been key enabler in effecting two acquisitions in the past six years that expanded our operations and was again instrumental in driving our recent Tech-IT acquisition that will give CTG broader end-to-end capabilities to better-serve our clients. Together, this team has greatly contributed to our success in Europe, where CTG has recorded eight consecutive years of revenue growth,” commented Filip Gydé, current Executive Vic
Jazwares Announces Partnership with Kellytoy for Russ Berrie™ Worldwide15.2.2019 01:00:00 | Pressemelding
Sunrise, FL, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Jazwares LLC, a global leader in toys and licensing, announced today that its affiliate Zag Toys, LLC (“Zag Toys”) formed a strategic partnership for their wholly owned brand Russ Berrie™, with Kellytoy, an influential manufacturer and distributor of plush toys and pet products. This relationship will carry on the 50+ year legacy of the Russ Berrie™ brand, positioning it globally as the premier plush brand on retail shelves in Fall 2019. Kellytoy will market the Russ Berrie™ brand through its global distribution channels, which include almost every market segment. “Working together with Kellytoy will maximize the Russ Berrie™ legacy,” says Judd Zebersky, Jazwares CEO and President. “By leveraging Russ Berrie™ and its reputation for quality and commitment to “Make Someone Happy™” with Kellytoy’s global footprint we’ll secure placement in retailers all around the world, putting Russ Berrie™ at the forefront of today’s plush presence at retai
PROFEPA report confirms no contamination of soil from overflow of contingency pond at the San Jose Mine, Mexico in October 201814.2.2019 19:46:00 | Pressemelding
VANCOUVER, British Columbia, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) is pleased to report that the Federal Attorney's Office for Environmental Protection (PROFEPA) has completed its investigation into the overflow of the contingency pond at the dry stack tailings facility at the San Jose Mine on October 8, 2018, which was caused by heavy seasonal rains (refer to Fortuna news release dated October 11, 2018). PROFEPA’s final report confirms that the overflow did not contaminate soil, and therefore no remediation is required. The Company awaits a final report from the Mexican National Water Commission (CONAGUA). The Company reiterates its commitment to safeguarding the wellbeing of the environment, local communities and our work force. About Fortuna Silver Mines Inc. Fortuna is a growth oriented, precious metals producer focused on mining opportunities in Latin America. Our primary assets are the Caylloma silver Mine in southern Peru, the San Jos
Cloudian HyperStore Named 2018 Product of the Year in Software-defined and Cloud Storage by Storage Magazine14.2.2019 19:10:00 | Pressemelding
Also Wins Best Hybrid Cloud Solution in 2018-2019 Cloud Awards, Further Reinforcing Company’s Object Storage Leadership SAN MATEO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Cloudian today announced two top industry awards for its HyperStore object storage platform. The awards are the latest honors for the company’s limitlessly scalable, highly cost-effective solution, which provides the industry’s best S3 compatibility and seamless data management across on-premises and public cloud environments. 2018 Software-defined and Cloud Storage Product of the Year TechTarget’s Storage magazine and SearchStorage.com named HyperStore 7 as the Gold winner in the Software-defined and Cloud Storage category of the 2018 Products of the Year Awards. The judging panel of analysts, consultants, users and TechTarget writers were “particularly impressed with [HyperStore’s] functionality.” In addition, the solution received high marks for innovation, value and ease of integration, use and manageability, en
Hot Silicon Valley Tech Firm Grows in Krakow14.2.2019 16:28:00 | Pressemelding
SignalFx Opens Research and Development and Support Office; Hires Industry Veteran Martin Burlinski, Head of Engineering, EMEA SAN MATEO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- SignalFx, the leader in real-time cloud monitoring for infrastructure, microservices, and applications, is announcing the opening of a new Research, Development and Support Office in Krakow, Poland and the addition of Martin Burlinski, Head of Engineering, EMEA. The new Krakow facility will enable SignalFx to accelerate product development and provide broader global support for its customers. “We were naturally attracted to Krakow not only because of its strong existing talent pool of world-class engineers but also its proximity to recent graduates from the city’s many universities,” said Leonid Igolnik, EVP Engineering for SignalFx. “We have an immediate need for engineers to become a core part of our company working side-by-side with our Silicon Valley and Research Triangle Park teams. With a global client
HL7 and SNOMED International Announce Agreement for Free Set of Terms for Use with International Patient Summary14.2.2019 15:00:00 | Pressemelding
Orlando, Fl., Feb. 14, 2019 (GLOBE NEWSWIRE) -- SNOMED International and Health Level Seven International (HL7) announce today the formalization of a license agreement in which a relevant ‘Free for Use’ Set of SNOMED CT coded concepts will be used within the HL7 International Patient Summary (IPS). Health Level Seven International (HL7) is a not-for-profit, ANSI-accredited standards developing organization dedicated to providing a comprehensive framework and related standards for the exchange, integration, sharing and retrieval of electronic health information that supports clinical practice and the management, delivery and evaluation of health services. SNOMED International is a not-for-profit, member-owned and driven international organization charged with maintaining and releasing the SNOMED CT clinical terminology product; the world’s most comprehensive clinical terminology. Presently comprised of 38 Member countries globally, SNOMED International supports the role that structured